標(biāo)題: Titlebook: Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays; Franz J. Hock,Michael K. Pugsley Reference work 2024Latest edition Sprin [打印本頁] 作者: Iodine 時(shí)間: 2025-3-21 17:17
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays影響因子(影響力)
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays影響因子(影響力)學(xué)科排名
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays網(wǎng)絡(luò)公開度
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays被引頻次
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays被引頻次學(xué)科排名
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays年度引用
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays年度引用學(xué)科排名
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays讀者反饋
書目名稱Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays讀者反饋學(xué)科排名
作者: 騙子 時(shí)間: 2025-3-21 21:37 作者: intimate 時(shí)間: 2025-3-22 02:20 作者: 排斥 時(shí)間: 2025-3-22 07:48 作者: 有說服力 時(shí)間: 2025-3-22 09:03 作者: Oratory 時(shí)間: 2025-3-22 16:11
Blood Constituents and Safety Pharmacology: In Vitro and In Vivo Thrombosis and Hemostasis Assaysf the proteases involved in thrombogenesis, including tissue factor, coagulation factors, adhesion molecules, and fibrinolytic inhibitors, has provided insights into the mechanisms by which thrombogenesis can be pharmacologically controlled..Pharmaceutical industry has played a key role not only in 作者: Oratory 時(shí)間: 2025-3-22 18:48
Metabolism Pharmacologyjury potential. We present pharmacological methods aiming to elucidate the potential undesirable effect of compounds on intermediary carbohydrate and lipid metabolism resulting in hypo- or hyperglycemia, hyperlipidemia, and insulin resistance, which can ultimately provoke life-threatening hypoglycem作者: 刺穿 時(shí)間: 2025-3-22 22:37 作者: MORPH 時(shí)間: 2025-3-23 02:05
Liver Systems in Safety Pharmacologyn liver-on-a-chip technology are highlighted, showcasing the design, applications, and success stories of these innovative devices in safety pharmacology. This book chapter also addresses biomarkers for liver safety assessment, emphasizing both traditional serum markers and emerging biomarkers for n作者: 不要不誠實(shí) 時(shí)間: 2025-3-23 06:19
Drug Addiction and Drug Dependencyioned place preference, and intracranial self-stimulation. This chapter outlines approaches commonly employed in studies of abuse and dependence liability assessments and highlights recent trends and advances in the utilization of each approach over the last decade.作者: Immunoglobulin 時(shí)間: 2025-3-23 11:47
ribed with subsequent considerations relevant for developing an integrated risk assessment considering the early phase I clinical data. In addition, current challenges and future directions of the regulatory process are discussed.作者: 災(zāi)難 時(shí)間: 2025-3-23 17:00
ictive values, etc. Currently available, systematic translation analyses for safety pharmacology studies are also discussed. Overall, robust data is available for establishing translation of cardiovascular assays, especially assays for assessing the risk of delayed ventricular repolarization, QT pro作者: 綠州 時(shí)間: 2025-3-23 20:03 作者: Extort 時(shí)間: 2025-3-24 01:57
y studies is that they are performed under unstressed and physiological conditions. Despite the preference for the use of conscious animals, SP studies are also performed using anesthetized animal models. Anesthetized animal studies allow for a more in-depth evaluation of possible drug effects on th作者: GEON 時(shí)間: 2025-3-24 02:26 作者: NIL 時(shí)間: 2025-3-24 10:13 作者: 粉筆 時(shí)間: 2025-3-24 11:31
jury potential. We present pharmacological methods aiming to elucidate the potential undesirable effect of compounds on intermediary carbohydrate and lipid metabolism resulting in hypo- or hyperglycemia, hyperlipidemia, and insulin resistance, which can ultimately provoke life-threatening hypoglycem作者: 尖酸一點(diǎn) 時(shí)間: 2025-3-24 17:34 作者: MURAL 時(shí)間: 2025-3-24 20:39 作者: PACK 時(shí)間: 2025-3-24 23:58 作者: 文字 時(shí)間: 2025-3-25 03:58 作者: ALE 時(shí)間: 2025-3-25 09:42 作者: JOG 時(shí)間: 2025-3-25 13:10 作者: 圓桶 時(shí)間: 2025-3-25 17:59
Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays978-3-031-35529-5作者: braggadocio 時(shí)間: 2025-3-25 21:07
Status of Safety Pharmacology and Present Guidelinesin detail. A detailed guideline development after the more frequently observed QT-time prolongation is also described. The different strategies prior to the implementation of the ICH Guidelines are also discussed.作者: Ferritin 時(shí)間: 2025-3-26 03:14
Overview of the ICH E14/S7B: Questions and Answerstes (TdP) has remained a significant burden in pharmaceutical drug development, leading to drug withdrawal from the marketplace and late-stage attrition in research and development. This chapter provides an overview of the regulatory guidance that emerged to address this issue with an emphasis on th作者: 合法 時(shí)間: 2025-3-26 06:44 作者: BAN 時(shí)間: 2025-3-26 11:01
Central Nervous System (CNS) Safety Pharmacology Studiesrvous system (CNS) is one of the vital systems which need to be protected against the potential harmful effects of test items. The present chapter includes some guidance for the selection and the realization of preclinical tests used in the context of CNS safety pharmacology. In contrast with a tren作者: SLAG 時(shí)間: 2025-3-26 16:43 作者: 藥物 時(shí)間: 2025-3-26 18:33
In Vivo Methods in Cardiovascular Safety Pharmacologyon the heart and peripheral vasculature as well as assess any other effect that may secondarily lead to an activation or depression of cardiovascular performance. According to the cardiovascular SP guidelines, telemetry studies in conscious large animals are preferred for evaluation of drug-induced 作者: Foreshadow 時(shí)間: 2025-3-27 00:21 作者: 遠(yuǎn)足 時(shí)間: 2025-3-27 02:13 作者: 身體萌芽 時(shí)間: 2025-3-27 05:40
Blood Constituents and Safety Pharmacology: In Vitro and In Vivo Thrombosis and Hemostasis Assaysromboembolism, acute coronary syndromes, cerebral vascular ischemic and thrombotic events, and diseases associated with thrombotic disorders has provided additional insights toward the development of various therapeutic approaches to control these pathogenic events. The roles of plasmatic proteins, 作者: 知識(shí) 時(shí)間: 2025-3-27 10:16 作者: 人工制品 時(shí)間: 2025-3-27 14:50 作者: 虛情假意 時(shí)間: 2025-3-27 20:25
Current Assays in Endocrine Safety Pharmacologylated findings in repeated-dose toxicity studies. Such findings may be changes in organ weight and/or histopathology, abnormal findings in biochemistry, and/or endocrine biomarkers. They are needed to detect undesirable pharmacodynamic effects of a substance on endocrine system in relation to exposu作者: Ingredient 時(shí)間: 2025-3-28 00:52
Skin Pharmacologyrial chemicals, and pesticides. In this chapter, we will discuss the rationale, procedure, accuracy, safety, advantages, and disadvantages of these assays when experimented with in vitro and in vivo, both in animals (mice, guinea pigs, …) and humans..The Organisation for Economic Co-operation and De作者: 膽小鬼 時(shí)間: 2025-3-28 03:55
Liver Systems in Safety Pharmacologyk chapter delves into various aspects of liver function, metabolism, and toxicity assessment in the context of drug development. Beginning with an overview of the liver’s role in drug metabolism and its importance in ensuring drug safety, the discussion progresses to explore the intricacies of liver作者: 組成 時(shí)間: 2025-3-28 09:05
Peripheral Nervous SystemExp Pathol Pharmakol 93:72–91, 1922; Schaumann, Naunyn-Schmiedeberg’s Arch Exp Pathol Pharmakol 190:30–51, 1938; Camougis and Takman, Nerve and nerve-muscle preparations (as applied to local anesthetics). In: Schwartz A (ed) Methods in pharmacology, vol 1. Appleton-Century-Crofts. Educational Divisi作者: 不出名 時(shí)間: 2025-3-28 11:48 作者: 單獨(dú) 時(shí)間: 2025-3-28 16:10 作者: 遺忘 時(shí)間: 2025-3-28 21:36 作者: 止痛藥 時(shí)間: 2025-3-29 02:25 作者: lipids 時(shí)間: 2025-3-29 06:32 作者: AGATE 時(shí)間: 2025-3-29 07:21
Renal System in Safety Pharmacologyf functional nephron mass ((Newman DJ, Price CP. Tietz textbook of clinical chemistry. WB Saunders, Philadelphia, 1999)1999). Thus, assessment of the plasma level of such a constituent can serve as a biomarker of renal function, and several have been used extensively for this purpose.作者: Expressly 時(shí)間: 2025-3-29 15:27
Peripheral Nervous Systemmuscle preparations (as applied to local anesthetics). In: Schwartz A (ed) Methods in pharmacology, vol 1. Appleton-Century-Crofts. Educational Division, Meredith Corp, New York, pp 1–40, 1971). Special local tolerance tests have been developed for each of these applications including peridural and intrathecal injections.作者: 脾氣暴躁的人 時(shí)間: 2025-3-29 18:09
https://doi.org/10.1007/978-3-642-61426-2re in the therapeutic range and above. The main objective is to decide whether the test compound can be administered to humans, which effects need to be monitored in clinical pharmacology and which clinical investigations are required for the risk evaluation.作者: Exposition 時(shí)間: 2025-3-29 23:11 作者: Ataxia 時(shí)間: 2025-3-30 02:46
ent and decision making.Of use for government institutions a.Many aspects of drug safety have become an outstanding and even persistent issue and may occur during the process of both drug discovery and development. Until 15 years ago, drug discovery and evaluation was primarily a sequential process 作者: Grating 時(shí)間: 2025-3-30 06:43 作者: FID 時(shí)間: 2025-3-30 10:50 作者: 蔓藤圖飾 時(shí)間: 2025-3-30 14:57 作者: LIMIT 時(shí)間: 2025-3-30 20:08 作者: 不合 時(shí)間: 2025-3-31 00:17 作者: 直覺沒有 時(shí)間: 2025-3-31 03:58
Computational Cardiac Safety Testingtainty, how to assess simulation reliability and reproducibility, and therefore how to establish trust in model predictions. We examine applications of simulations to date, particularly in the context of the comprehensive in vitro proarrhythmia Assay (CiPA). The chapter concludes with a discussion of future avenues for research.作者: 夾克怕包裹 時(shí)間: 2025-3-31 05:20 作者: packet 時(shí)間: 2025-3-31 11:46 作者: 反省 時(shí)間: 2025-3-31 16:30
Springer Nature Switzerland AG 2024作者: Blanch 時(shí)間: 2025-3-31 21:31
The adverse effects of new chemical entities (NCE) in animals and humans can manifest as changes in the structural, biochemical, or physiological status of the organism (see Fig. .). In the preclinical safety assessment process, toxicological procedures have traditionally focused on the structural and biochemical consequences of drug actions.作者: nettle 時(shí)間: 2025-4-1 01:39
Safety Pharmacology: IntroductionThe adverse effects of new chemical entities (NCE) in animals and humans can manifest as changes in the structural, biochemical, or physiological status of the organism (see Fig. .). In the preclinical safety assessment process, toxicological procedures have traditionally focused on the structural and biochemical consequences of drug actions.作者: declamation 時(shí)間: 2025-4-1 05:46
